

## ACKNOWLEDGEMENT TO REFEREES

© Springer Nature Switzerland AG 2022

Dear Reader,

Welcome to the final issue of *Pharmaceutical Medicine* for 2022.

As we reach the end of another successful year, I would like to thank all those who have contributed their valuable time and effort to the journal over the past 12 months.

The Section Editors and I would like to begin by thanking the authors who have contributed articles to *Pharmaceutical Medicine* over the course of 2022. The skill and dedication of these experts is critical to the continued success of the journal.

The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would therefore like to thank the following individuals who acted as reviewers for *Pharmaceutical Medicine* in the last 12 months:

Mohamed Abou-el-Enein, USA  
Lisbeth Barkholt, Sweden  
Andrew Bate, UK  
Saleh A. Bawazir, Saudi Arabia  
Alexander Bedenkov, UK  
Shachi Bista, Sweden  
Marc Buyse, Belgium  
Brent Ower Caldwell, New Zealand  
Orin Chisholm, Australia  
Lesong Conteh, UK  
Chelsie W.W. Counsell, USA  
Douglas Coyle, Canada  
Saskia de Morée, Canada  
Guy S. Diamond, USA  
Isabelle S. Durand-Zaleski, France  
Brian David Edwards, UK  
Vicki Edwards, UK  
Simon Erridge, UK  
Ana Fraguas-Sanchez, Spain  
Louis Preston Garrison Jr, USA  
Monalisa Ghosh, USA  
Henry G. Grabowski, USA  
Stephen Groft, USA  
Sarah Hall, UK  
Jill Harkavy-Friedman, USA  
Brett Hauber, USA  
Cecilia J. Hillard, USA  
Carsten Hjorthøj, Denmark

Alan M. Hochberg, Switzerland  
Thomas J. Hwang, USA  
Liza-Marie Johnson, USA  
Seetharama Jois, USA  
Sigal Kaplan, Israel  
Ronald Kiguba, Uganda  
Marie-Laure Kürzinger, France  
Samantha Lane, UK  
Paul Lartey, USA  
Catherine Y. Lau, Canada  
Sharon B. Love, UK  
Murray Lumpkin, USA  
Tamra Lysaght, Singapore  
Terri Madison, USA  
Hideki Maeda, Japan  
Jonathan Mahnken, USA  
Olivia Mahaux, Belgium  
David Morgan, UK  
Monica A. Muñoz, USA  
Carl Naraynassamy, UK  
Koji Oba, Japan  
Olga Ostrovsky, USA  
Steve Pascolo, Switzerland  
Siddharth Patel, USA  
Raffaella Ravinetto, Belgium  
Frances J. Richmond, USA  
David B. Ridley, USA  
Paul D. Robbins, USA

Bruno Rodrigue, Canada  
 Kaye Rolls, Australia  
 Jakob Daniel Rudzki, Austria  
 Andreas Seiter, USA  
 Meredith Yearsley, Smith, USA  
 Julia Spoendlin, Switzerland  
 Thomas Sudhop, Germany  
 Maw Pin Tan, Malaysia  
 Philippe Thomas, Germany  
 Christopher J. Twelves, UK

Kristel Van de Voorde, Belgium  
 Sibren van den Berg, The Netherlands  
 Jan Van Parijs, Belgium  
 Robert Vander Stichele, Belgium  
 Katarina Vucic, Croatia  
 Timothy E. Welty, USA  
 Ruth Wood, UK  
 Michael Zaiac, Switzerland  
 Yi Zhu, USA  
 Inge M. Zomerdijs, The Netherlands

Through the hard work of our authors and reviewers, we continue to see great gains in article usage. The most popular 2022 articles to date, in terms of downloads from SpringerLink, are:

- Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond. 36(1):1–10. <https://doi.org/10.1007/s40290-021-00412-w>
- Delivery Strategies for mRNA Vaccines. 36(1):11–20. <https://doi.org/10.1007/s40290-021-00417-5>
- Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core. 36(2):63–69. <https://doi.org/10.1007/s40290-022-00419-x>
- Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. 36(2):99–129. <https://doi.org/10.1007/s40290-022-00420-4>
- Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. 36(3):163–171. <https://doi.org/10.1007/s40290-022-00428-w>
- Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets. 36(3):153–161. <https://doi.org/10.1007/s40290-022-00429-9>
- The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic. 36(2):131–142. <https://doi.org/10.1007/s40290-022-00421-3>
- Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns. 36(1):33–46. <https://doi.org/10.1007/s40290-021-00414-8>
- Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument. 36(1):47–57. <https://doi.org/10.1007/s40290-021-00413-9>
- Digital Additional Risk Minimization Measures: An Exploratory Study Using Qualitative Feedback from Healthcare Professionals and Patients Across Six Countries. 36(1):21–32. <https://doi.org/10.1007/s40290-021-00415-7>

We gratefully acknowledge all of the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

Dr Peter R. Arlett, MD MRCP. European Medicines Agency, Amsterdam, The Netherlands  
 Dr Sander Becker, MD. Consultants in Pharmaceutical Medicine, Rose Bay North, NSW, Australia  
 Dr Ambrogio Bottoni, MD. Pfizer Inc., Milan, Italy  
 Dr Torbjörn Callréus, MD PhD. Malta Medicines Authority, San Ġwann, Malta  
 Dr Norbert Clemens, MD PhD CPI. Association of Clinical Research Professionals Academy Board of Trustees, Heidelberg, Germany  
 Mr Francis P. Crawley, PhL. Good Clinical Practice Alliance – Europe, Brussels, Belgium  
 Dr Jean-Paul Deslypere, MD PhD. Council on Education in Pharmaceutical Medicine, Singapore  
 Dr Francesco De Tomasi, MD. Italian Society of Pharmaceutical Medicine, Milan, Italy  
 Dr Georg Ferber, PhD. Statistik Georg Ferber GmbH, Riehen, Switzerland  
 Professor Anthony W. Fox, MSc MBBS MD FPPM FRCP DipPharmMed MCSFS DipFHI MFMLM CBiol. The Inns of Court College of Advocacy, London, England  
 Dr Claudio Fracasso, MD. Pfizer S.r.l., Rome, Italy  
 Professor Sanjay K. Garg, PhD. University of South Australia, Adelaide, SA, Australia  
 Dr E. Stewart Geary, MD. Eisai Co. Ltd., Tokyo, Japan  
 Mr Kenneth A. Getz, MBA. Tufts University Medical School, Boston, MA, USA  
 Mr Ari Gnanasakthy, BSc MSc MBA. RTI Health Solutions, Research Triangle Park, NC, USA

Dr Ulrich Granzer, PhD. Granzer Regulatory Consulting & Services, Munich, Germany  
Professor Jan D. Hirsch, BPharm PhD. University of California, Irvine, CA, USA  
Mr Alan Hunter, LLB BPharm, FPS, FTOPRA. Independent Pharmaco-Legal Adviser, Staines, England  
Dr Ambrose O. Isah, MD. University of Benin, Benin, Nigeria, Africa  
Dr Greg Koski, MD PhD CPI. Alliance for Clinical Research Excellence and Safety, Cambridge, MA, USA  
Dr Marlene Llopíz Avíles, BA MD MPH. Association of Medical Specialists in the Pharmaceutical Industry, Mexico City, Mexico  
Dr Marcelo Marotti, MD PhD. AstraZeneca UK Ltd., Macclesfield, England  
Dr Peter G. M. Mol, PhD, PharmD. Dutch Medicines Evaluation Board, Utrecht, The Netherlands  
Dr Shunsuke Ono, PhD. University of Tokyo, Tokyo, Japan  
Dr María Proupín-Pérez, PhD. CSL Behring Innovation GmbH, Marburg, Germany  
Professor Sir Michael Rawlins, BSc MD FRCP FFPM. Medicines and Healthcare Products Regulatory Agency, London, England  
Dr Klaus Rose, MD MS. Klausrose Consulting, Riehen, Switzerland  
Professor Sam Salek, BPharm PhD RPh MRPSGB FFPM FESCP. University of Hertfordshire, Hatfield, England  
Professor Grannum R. Sant, MD FRCS FACS. Tufts University School of Medicine, Boston, MA, USA  
Dr Ruth Savage, MB BS MSc. University of Otago, Dunedin, New Zealand  
Dr Jeffrey W. Sherman, MD FACP. Horizon Pharma, Deerfield, IL, USA  
Dr Honorio Silva, MD. International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine, New York, NY, USA  
Dr Noel Snell, FRCP FFPM FRIPH FIBiol. National Heart & Lung Institute, London, England  
Professor Peter D. Stonier, BA BSc PhD MB ChB MRCPsych FRCP FRCPE FFPM. King's College London, London, England  
Dr Robert Temple, MD. Center for Drug Evaluation & Research, Food and Drug Administration, Rockville, MD, USA  
Professor Rolf Teschke, MD. Klinikum Hanau, Hanau, Germany  
Professor Stuart R. Walker, BSc PhD CChem CBiol FRSC FIBiol FInstD FRCPath. Centre for Innovation in Regulatory Science, Carshalton, England

We hope that you have found the articles published throughout 2022 to be both interesting and informative. The editors have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in the pharmaceutical medicine field in 2023, when the journal will also receive its first Impact Factor.

With best wishes from the Editor and staff of *Pharmaceutical Medicine*.

Sue Pochon